报价延迟最少15分钟:2025/09/12 07:26 EDT
盘前时段
|
||||
|
-- 
|
|
|
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.6
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-1.26/-1.07
|
|
企业价值
12.69M
|
| 资产负债 |
|
每股账面净值
0.61
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
119.80K
|
|
每股收益
0.02
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
报价延迟最少15分钟：2025/09/12 07:26 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue. |
